Skip to main content

Peer Review reports

From: Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib

Original Submission
23 Mar 2018 Submitted Original manuscript
14 May 2018 Reviewed Reviewer Report - Hsin-An Hou
7 Jul 2018 Reviewed Reviewer Report - Carlo Gambacorti-Passerini
11 Jul 2018 Reviewed Reviewer Report - Reviewer 2
10 Aug 2018 Author responded Author comments - Radowan Elnair
Resubmission - Version 2
10 Aug 2018 Submitted Manuscript version 2
5 Sep 2018 Reviewed Reviewer Report - Hsin-An Hou
6 Sep 2018 Reviewed Reviewer Report - Reviewer 2
19 Sep 2018 Author responded Author comments - Radowan Elnair
Resubmission - Version 3
19 Sep 2018 Submitted Manuscript version 3
17 Oct 2018 Author responded Author comments - Radowan Elnair
Resubmission - Version 4
17 Oct 2018 Submitted Manuscript version 4
Publishing
29 Oct 2018 Editorially accepted
12 Nov 2018 Article published 10.1186/s12885-018-5004-3

You can find further information about peer review here.

Back to article page